Blood sampling for pharmacokinetics was carried out at every visit (weeks 18, 12 and 16, EoT and follow-up) and blood sampling for exploratory biomarkers was carried out at weeks 1, 5, 8 and 12, EoT and follow-up
Submit the required weight verification
Plasma AUC levels of sitagliptin were increased approximately 2-fold and 4-fold in patients with moderate renal insufficiency and in patients with severe renal insufficiency, including patients with ESRD on hemodialysis, respectively
Lab testing is not universally required for GLP-1 prescriptions
Because MariTide targets these two separate pathways associated with obesity, we hypothesize that it could result in rapid, substantial and sustained weight loss without the weight rebound often observed with other approved anti-obesity medications